Market research and consulting firm Frost & Sullivan said on Tuesday that it has awarded ZAGENO, a procurement orchestration platform for life sciences, its 2026 North America Life Sciences E-Commerce Company of the Year Recognition for helping transform life sciences e-commerce beyond traditional online purchasing into a unified procurement orchestration platform.
By serving as a single entry point into scientific procurement, ZAGENO enables scientists, procurement teams, suppliers, and enterprise systems to operate within one connected workflow, reducing procurement friction while improving governance, visibility, and operational efficiency across research organisations.
"We're honoured to receive this recognition from Frost & Sullivan," commented Florian Wegener, CEO and co-founder of ZAGENO. "As research organisations become more connected and more complex, procurement has evolved far beyond purchasing. Our vision has always been to simplify that complexity by bringing scientists, procurement teams, suppliers, and enterprise systems together through a single procurement orchestration platform. We're proud to see that vision recognised, and even more excited about what's ahead for our customers."
Each year, Frost & Sullivan honours one company with its Company of the Year Recognition for organisations that demonstrate exceptional growth, innovation, and customer value. The selection process includes rigorous research, competitive benchmarking, and in-depth industry analysis.
Genezen agrees manufacturing collaboration with Galibra Neuroscience
Viking Therapeutics launches Phase 3 clinical programme for oral VK2735 in obesity
Coya Therapeutics plans open-label extension of COYA 302 ALS trial
Takeda reports positive Phase 2/3 results for investigational immunodeficiency therapy
Galderma to acquire ZO Skin Health for USD1.5bn to expand skincare portfolio
Orexo reports encouraging initial bioavailability results for oral semaglutide formulation
Pharming reports positive Phase II results for leniolisib in genetic immune disorders
Telix to present 20 abstracts on cancer theranostics at EANM Congress
CelLBxHealth secures USD65,000 pharmaceutical research contract
FDA grants Breakthrough Therapy Designation to Legacy Healthcare's CINAINU (LH-8)
Racura Oncology receives approval for RC220 trial to proceed to higher dose
Blue Lake Biotechnology reports interim data from Phase 1/2a paediatric clinical trial of BLB201
ArkBio reports FDA clearance of IND application for AK0406
Enodia Therapeutics partners with Pfizer on Sec61-targeting drug development